PURPOSE: Cornea confocal microscopy is emerging as a clinical tool to evaluate the development and progression of diabetic neuropathy. The purpose of these studies was to characterize the early changes in corneal sensitivity and innervation in a rat model of type 1 diabetes in relation to standard peripheral neuropathy endpoints and to assess the effect of Ilepatril, a vasopeptidase inhibitor which blocks angiotensin converting enzyme and neutral endopeptidase, on these endpoints. METHODS: Streptozotocin-diabetic rats 8 weeks duration were treated with or without Ilepatril for the last 6 weeks of the experimental period. Afterwards, standard diabetic neuropathy endpoints, subbasal corneal nerves and innervation of the epithelium, corneal sensitivity using a Cochet-Bonnet esthesiometer, and vascular reactivity of the posterior ciliary artery were examined. RESULTS: Diabetes caused a decrease in nerve conduction velocity, thermal hypoalgesia, and a reduction in intraepidermal nerve fiber profiles. In the cornea there was a decrease in corneal nerve fibers innervating the epithelium and corneal sensitivity, but subbasal corneal nerve fibers was not changed. Vascular relaxation in response to acetylcholine was decreased in the posterior ciliary artery. These defects were partially to completely prevented by Ilepatril treatment. CONCLUSIONS: These studies suggest that in type 1 diabetic rats decreased innervation of the cornea epithelium occurs early in diabetes and prior to a detectable decrease in subbasal corneal nerves and that these and other diabetic neuropathy-related defects can be partially to completely prevented by a vasopeptidase inhibitor.
PURPOSE: Cornea confocal microscopy is emerging as a clinical tool to evaluate the development and progression of diabetic neuropathy. The purpose of these studies was to characterize the early changes in corneal sensitivity and innervation in a rat model of type 1 diabetes in relation to standard peripheral neuropathy endpoints and to assess the effect of Ilepatril, a vasopeptidase inhibitor which blocks angiotensin converting enzyme and neutral endopeptidase, on these endpoints. METHODS:Streptozotocin-diabeticrats 8 weeks duration were treated with or without Ilepatril for the last 6 weeks of the experimental period. Afterwards, standard diabetic neuropathy endpoints, subbasal corneal nerves and innervation of the epithelium, corneal sensitivity using a Cochet-Bonnet esthesiometer, and vascular reactivity of the posterior ciliary artery were examined. RESULTS:Diabetes caused a decrease in nerve conduction velocity, thermal hypoalgesia, and a reduction in intraepidermal nerve fiber profiles. In the cornea there was a decrease in corneal nerve fibers innervating the epithelium and corneal sensitivity, but subbasal corneal nerve fibers was not changed. Vascular relaxation in response to acetylcholine was decreased in the posterior ciliary artery. These defects were partially to completely prevented by Ilepatril treatment. CONCLUSIONS: These studies suggest that in type 1 diabeticrats decreased innervation of the cornea epithelium occurs early in diabetes and prior to a detectable decrease in subbasal corneal nerves and that these and other diabetic neuropathy-related defects can be partially to completely prevented by a vasopeptidase inhibitor.
Authors: Christine L Oltman; Eric P Davidson; Lawrence J Coppey; Travis L Kleinschmidt; Brian Dake; Mark A Yorek Journal: Eur J Pharmacol Date: 2010-10-30 Impact factor: 4.432
Authors: Egemen Savaskan; Karin U Löffler; Fides Meier; Franz Müller-Spahn; Josef Flammer; Peter Meyer Journal: Ophthalmic Res Date: 2004 Nov-Dec Impact factor: 2.892
Authors: R A Malik; P Kallinikos; C A Abbott; C H M van Schie; P Morgan; N Efron; A J M Boulton Journal: Diabetologia Date: 2003-05-09 Impact factor: 10.122
Authors: Mitra Tavakoli; Cristian Quattrini; Caroline Abbott; Panagiotis Kallinikos; Andrew Marshall; Joanne Finnigan; Philip Morgan; Nathan Efron; Andrew J M Boulton; Rayaz A Malik Journal: Diabetes Care Date: 2010-04-30 Impact factor: 19.112
Authors: Christine L Oltman; Eric P Davidson; Lawrence J Coppey; Travis L Kleinschmidt; Donald D Lund; Mark A Yorek Journal: Obesity (Silver Spring) Date: 2008-01 Impact factor: 5.002
Authors: Irina G Obrosova; Fei Li; Omorodola I Abatan; Mark A Forsell; Katalin Komjáti; Pal Pacher; Csaba Szabó; Martin J Stevens Journal: Diabetes Date: 2004-03 Impact factor: 9.461
Authors: Krisandra Kneer; Michael B Green; Jenna Meyer; Celeste B Rich; Martin S Minns; Vickery Trinkaus-Randall Journal: Exp Eye Res Date: 2018-06-05 Impact factor: 3.467
Authors: Maxwell S Stem; Munira Hussain; Stephen I Lentz; Nilesh Raval; Thomas W Gardner; Rodica Pop-Busui; Roni M Shtein Journal: J Diabetes Complications Date: 2014-06-17 Impact factor: 2.852
Authors: Matthew S Yorek; Alexander Obrosov; Hanna Shevalye; Sergey Lupachyk; Matthew M Harper; Randy H Kardon; Mark A Yorek Journal: J Peripher Nerv Syst Date: 2014-09 Impact factor: 3.494
Authors: Hanna Shevalye; Matthew S Yorek; Lawrence J Coppey; Amey Holmes; Matthew M Harper; Randy H Kardon; Mark A Yorek Journal: J Neurophysiol Date: 2015-04-29 Impact factor: 2.714
Authors: Mehrnoosh Saghizadeh; Irina Epifantseva; David M Hemmati; Chantelle A Ghiam; William J Brunken; Alexander V Ljubimov Journal: Invest Ophthalmol Vis Sci Date: 2013-12-17 Impact factor: 4.799